Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The dual checkpoint inhibitor regimen of nivolumab and ipilimumab represents a standard of care for the first-line treatment of metastatic renal cell carcinoma.
“The dual CPI regimen of nivolumab (a programmed death-1 (PD-1) inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor) represents a standard of care for the first-line treatment of mRCC6,7.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003 · see citing works
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · see citing works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752 · see citing works
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · see citing works
Self-citationTemsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645 · see citing works
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.029 · Cited by 3,088 · see citing works
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · see citing works
Self-citationHsieh, J. J.-D., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L. K., Schmidinger, M., Heng, D. Y. C., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,797 · see citing works
Self-citationSternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C. A., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,470 · see citing works
Andrews, D. W., Scott, C., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner‐Wasik, M., Demas, W. F., Ryu, J. K., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,418 · see citing works
Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S. C., Kryscio, R. J., Mohiuddin, M., & Young, B. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66954-1 · Cited by 2,382 · see citing works
Escudier, B. J., Pluzanska, A., Koralewski, P., Ravaud, A., Sergio Bracarda, A., Szczylik, C. A., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,216 · see citing works
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,139 · see citing works
Köcher, M., Soffietti, R., Abacıoğlu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R., Carrié, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988 · see citing works
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D. F., Reeves, J. A., Hawkins, R. E., Guo, J., Nathan, P., Staehler, M. D., SOUZA, P. D., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,928 · see citing works
Rini, B. I., Escudier, B. J., Tomczak, P., Каприн, А. Д., Szczylik, C. A., Hutson, T. E., Michaelson, M. D., Горбунова, В. А., Gore, M. E., Русаков, И. Г., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,843 · see citing works
Self-citationSurvival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W. J., Amsterdam, A., & Ferrara, J. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,797 · see citing works
Epidemiology and risk factors for kidney cancer
Chow, W.-H., Dong, L. M., & Devesa, S. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.46 · Cited by 1,395 · see citing works
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336 · see citing works
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausová, J., Scagliotti, G. V., Sleeboom, H. P., Spencer, A. G., Vadhan‐Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,265 · see citing works
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260 · see citing works
Self-citationCabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B. J., Powles, T. B., Mainwaring, P. N., Rini, B. I., Donskov, F. N., Hammers, H. J., Hutson, T. E., Lee, J., Peltola, K. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,245 · see citing works
Self-citationGerlinger, M., Horswell, S. D., Larkin, J., Rowan, A., Salm, M., Varela, I., Fisher, R. A., McGranahan, N., Matthews, N., Santos, C. R., et al. (2014) · Nature Genetics · doi:10.1038/ng.2891 · Cited by 1,211 · see citing works
Choueiri, T. K., Escudier, B. J., Powles, T. B., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F. N., Roth, B. J., Peltola, K. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 964 · see citing works
Self-citationSunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Méjean, A., Ravaud, A., Thézenas, S., Colas, S., Beauval, J., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803675 · Cited by 955 · see citing works
Self-citationMotzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A. M., Eisen, T., Jassem, J., Żołnierek, J., Maroto, P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 951 · see citing works
Delahunt, B., Cheville, J. C., Martignoni, G., et al. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318299f0fb · Cited by 876 · see citing works
Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis
Flanigan, R. C., Mickisch, G., Sylvester, R. J., et al. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000110610.61545.ae · Cited by 872 · see citing works
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
Davis, C., Ricketts, C. J., Wang, M., Yang, L., Cherniack, A. D., Shen, H., Buhay, C., Kang, H.-J., Kim, S. C., Fahey, C. C., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.014 · Cited by 844 · see citing works
Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., Weaver, A. L., Parker, A. S., & Zincke, H. (2003) · Cancer · doi:10.1002/cncr.11234 · Cited by 840 · see citing works
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782 · see citing works
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705 · see citing works
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641 · see citing works
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 637 · see citing works
Haas, N. B., Manola, J. B., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C. J., Jewett, M. A. S., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 631 · see citing works
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy
Marconi, L. S., Dabestani, S., Lam, T. B. L., Hofmann, F., Stewart, F. J., Norrie, J. D., Bex, A., Bensalah, K., Canfield, S. E., Hora, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.072 · Cited by 608 · see citing works
Self-citationBex, A., Mulders, P., Jewett, M. A. S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5543 · Cited by 497 · see citing works
Self-citationActive surveillance of small renal masses: progression patterns of early stage kidney cancer.
Jewett, M., Mattar, K., Basiuk, J., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.03.030 · Cited by 473 · see citing works
Kapur, P., Peña‐Llopis, S., Christie, A. L., Zhrebker, L., Pavía-Jiménez, A., Rathmell, W. K., Xie, X., & Brugarolas, J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70584-3 · Cited by 466 · see citing works
Motzer, R. J., Nosov, D., Eisen, T., Bondarenko, I., Lesovoy, V., Lipatov, O. N., Tomczak, P., Lyulko, O., Alyasova, A. V., Hârza, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4940 · Cited by 445 · see citing works
Armstrong, A. J., Halabi, S., Eisen, T. G., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00515-x · Cited by 427 · see citing works
Patard, J., Kim, H. L., Lam, J. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.104 · Cited by 423 · see citing works
Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B. L., Michaelson, M. D., Hahn, O. M., Walsh, M. K., Olencki, T. E., Picus, J., Small, E. J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.012 · Cited by 399 · see citing works
Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71222-7 · Cited by 385 · see citing works
Motzer, R. J., Haas, N. B., Donskov, F. N., Gross‐Goupil, M., Varlamov, S., Kopyltsov, E., Lee, J., Melichar, B., Rini, B. I., Choueiri, T. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.5324 · Cited by 383 · see citing works
Tannir, N. M., Jonasch, E. W., Albiges, L. K., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Lim, Z. D., Tamboli, P., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 366 · see citing works
Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer
MacLennan, S. J., Imamura, M., Lapitan, M. C., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.039 · Cited by 355 · see citing works
Volpe, A., Kachura, J. R., Geddie, W. R., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.131 · Cited by 354 · see citing works
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C. W.-S., Ficarra, V., Murai, M., Oudard, S. M., Pantuck, A. J., Zigeuner, R. E., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 324 · see citing works
Local treatments for metastases of renal cell carcinoma: a systematic review
Dabestani, S., Marconi, L. S., Hofmann, F., Stewart, F. J., Lam, T. B. L., Canfield, S. E., Staehler, M. D., Powles, T. B., Ljungberg, B., & Bex, A. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70235-9 · Cited by 318 · see citing works
Self-citationMolecular Genetics of Clear-Cell Renal Cell Carcinoma
Brugarolas, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2003 · Cited by 309 · see citing works
ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
Brooks, S. A., Brannon, A. R., Parker, J. S., Fisher, J. C., Sen, O., Kattan, M. W., Hakimi, A. A., Hsieh, J. J.-D., Choueiri, T. K., Tamboli, P., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.035 · Cited by 304 · see citing works
Radiotherapy for renal-cell carcinoma
Meerleer, G. D., Khoo, V. S., Escudier, B. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70569-2 · Cited by 281 · see citing works
Self-citationMotzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C. A., Żołnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262 · see citing works
Self-citationActive surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Rini, B. I., Dorff, T. B., Elson, P. J., Suárez, C., Shepard, D. R., Wood, L. S., Humbert, J., Pyle, L., Wong, Y., Finke, J. H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30196-6 · Cited by 258 · see citing works
Rini, B. I., Goddard, A. D., Knezevic, D., Maddala, T., Zhou, M., Aydın, H., Campbell, S. C., Elson, P. J., Koscielny, S., Lopatin, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70167-1 · Cited by 254 · see citing works
Self-citationCella, D. F., Grünwald, V., Escudier, B. J., Hammers, H. J., George, S., Nathan, P., Grimm, M., Rini, B. I., Doan, J. F., Ivanescu, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30778-2 · Cited by 249 · see citing works
Self-citationPrognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
Iacovelli, R., Nolè, F., Verri, E., Renne, G., Paglino, C., Santoni, M., Rocca, M. C., Giglione, P., Aurilio, G., Cullurà, D., et al. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0392-7 · Cited by 179 · see citing works
Self-citationTFEB-amplified Renal Cell Carcinomas
Argani, P., Reuter, V. E., Zhang, L., Sung, Y., Ning, Y., Epstein, J. I., Netto, G. J., & Antonescu, C. R. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000720 · Cited by 161 · see citing works
A clear picture of renal cell carcinoma
Hakimi, A. A., Pham, C. G., & Hsieh, J. J.-D. (2013) · Nature Genetics · doi:10.1038/ng.2708 · Cited by 126 · see citing works
Schöffski, P., Woźniak, A., Escudier, B. J., Rutkowski, P. L., Anthoney, A., Bauer, S., Šufliarský, J., van Herpen, C., Lindner, L. H., Grünwald, V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.014 · Cited by 117 · see citing works
Self-citationDabestani, S., Beisland, C., Stewart, G. D., et al. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.02.010 · Cited by 106 · see citing works
Sun, M., Marconi, L. S., Eisen, T. G., Escudier, B. J., Giles, R. H., Haas, N. B., Harshman, L. C., Quinn, D. I., Larkin, J., Pal, S. K., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.05.002 · Cited by 89 · see citing works
Self-citationPreoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review
Prabhu, R. S., Patel, K. R., Press, R. H., et al. (2018) · Neurosurgery · doi:10.1093/neuros/nyy146 · Cited by 67 · see citing works
Malouf, G. G., Compérat, É., Yao, H., Mouawad, R., Lindner, V., Rioux-Leclercq, N. C., Verkarre, V., Leroy, X., Dainese, L., Classe, M., et al. (2016) · Scientific Reports · doi:10.1038/srep30988 · Cited by 55 · see citing works
Self-citationCollecting Duct Carcinomas Represent a Unique Tumor Entity Based on Genetic Alterations
Becker, F. O., Junker, K., Parr, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078137 · Cited by 39 · see citing works
Coffee consumption and risk of renal cell carcinoma
Antwi, S. O., Eckel‐Passow, J. E., Diehl, N. D., et al. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0913-z · Cited by 19 · see citing works
Clinical Progress in Renal Cancer
Leach, T. (2008) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2007.00838.x · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Brierley JD, Gospodarowicz MK and Wittekind C (eds). IUCC TNM Classification of Malignant Tumours, 8th edition. Oxford: John Wiley & Sons, Inc. 2016; 114-115.
Cited by
Sorted by citations
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515 · see citing works
Rizzo, A., Mollica, V., Santoni, M., Ricci, A. D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., & Massari, F. (2022) · European Urology Focus · doi:10.1016/j.euf.2021.03.001 · Cited by 91 · see citing works
- Authors
- Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A.
- Affiliations
- Institut Gustave Roussy (FR)
- University of Pavia (IT)
- Comprehensive Cancer Center Vienna (AT)
- Centre Hospitalier Universitaire de Rennes (FR)
- The Royal Free Hospital (GB)
- Institute of Cancer Research (GB)
- Essen University Hospital (DE)
- Kantonsspital St. Gallen (CH)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 30
- Issue
- 5
- Pages
- 706-720
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4237816489
- Cited by
- 1,151
- References
- 69
- Citations by year
- 2026: 66 · 2025: 133 · 2024: 179 · 2023: 182 · 2022: 235 · 2021: 174 · 2020: 122 · 2019: 57 · 2017: 1 · 2015: 2
- FWCI
- 108.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Exelixis
- Accuray
- European Association of Urology
- Eisai
- Astellas Pharma
- European Society for Medical Oncology
- Ipsen
- EUSA Pharma
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
- Keywords
- renal cell carcinoma, kidney cancer, diagnosis, treatment, follow-up
- MeSH terms
- Carcinoma, Renal Cell, Clinical Trials as Topic, Combined Modality Therapy, Female, Humans, Kidney Neoplasms, Male, Medical Oncology, Neoplasm Staging, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
